Table 3

Multivariate analysis of variables correlated with various clinical endpoints

End-pointFactorsHR95% CIP value
DFSAge (<50 years vs ≥50 years)1.0131.002 to 1.0240.018
T stage (T1–2 vs T3–4)1.0400.882 to 1.2270.642
N stage (N0–1 vs N2–3)1.4901.134 to 1.9580.004
Clinical stage (Ⅰ–Ⅱ vs Ⅲ–Ⅳb)1.0311.017 to 1.0450.000
Histology (WHO Ⅱ vs WHO Ⅲ)2.0251.358 to 3.0200.001
Tumour volume (<23 mL vs ≥23 mL)3.0251.277 to 7.1670.012
CNN (no vs yes)1.2250.967 to 1.5530.093
LDH (≤174 IU/L vs >174 IU/L)1.6691.110 to 2.9210.014
AC (no vs yes)0.8700.641 to 1.1800.370
OSAge (<50 years versus ≥50 years)1.8231.328 to 2.5020.000
T stage (T1–2 vs T3–4)1.1170.921 to 1.3550.260
N stage (N0–1 vs N2-–3)1.2761.004 to 1.6180.043
Clinical stage (Ⅰ–Ⅱ vs Ⅲ–Ⅳb)1.1630.881 to 1.5340.287
Histology (WHO Ⅱ vs WHO Ⅲ)0.6900.504 to 0.9320.016
CNN (no vs yes)2.1911.038 to 4.6250.040
Anaemia (no vs yes)0.5730.378 to 0.8680.009
Concurrent chemotherapy (no vs yes)0.8100.617 to 1.0640.130
IC (no vs yes)1.1580.978 to 1.3710.089
AC (no vs yes)1.4840.990 to 2.2220.056
DMFSN stage (N0–1 vs N2–3)2.3971.627 to 3.5310.000
Clinical stage (Ⅰ–Ⅱ vs Ⅲ–Ⅳb)1.1850.990 to 1.4190.064
Histology (WHOⅡ vs WHO Ⅲ)0.6540.412 to 1.0370.071
Tumour volume(<23 mL vs ≥23 mL)1.1130.931 to 1.3300.241
CNN (no vs yes)1.2101.013 to 1.4440.036
EBV-DNA copy number (<5000 copy/mL vs ≥5000 copy/mL)1.1830.965 to 1.4480.105
Anaemia (no vs yes)1.1160.881 to 1.4150.362
Concurrent chemotherapy (no vs yes)0.8160.599 to 1.1110.197
LRFSCNN (no vs yes)0.9300.521 to 1.6600.806
AC (no vs yes)1.2960.773 to 2.1720.326
RRFSIC (no vs yes)0.9460.198 to 4.5190.944
  • AC, adjuvant chemotherapy; CNN, cervical nodal necrosis; DFS, disease-free survival; DMFS, distant metastasis-free survival; IC, induction chemotherapy; LDH, lactic dehydrogenase; LRFS, local relapse-free survival; OS, overall survival; RRFS, regional relapse-free survival.